The Covid-19 vaccine, Covaxin, being developed by Bharat Biotech is now undergoing phase-3 trials, Krishna Ella, Chairman and Managing Director, Bharat Biotech said on Monday.
Speaking virtually at a programme organised by the Indian School of Business, Ella said the company is also working on another vaccine for COVID-19 which would be in the form of nasal drops and can be ready by next year.
"We partnered with ICMR for COVID-19 vaccine as we speak it entered the phase 3 trials," he said.
Bharat Biotech is the only vaccine company in the world which has BSL3 production facility (Biosafety level 3), he said.
Last month the vaccine maker said it had successfully completed interim analysis of Phase I and II trials of the vaccine and is initiating Phase-III trials in 26,000 participants.
Covaxin is being developed byBharatBiotech, in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).
The city-based vaccine maker had on October 2 sought the Drug Controller General of India's (DCGI) permission to conduct phase 3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine, sources said.
"We are working on another vaccine through nasal drops my feeling is by next year it will reach the population," Ella said.
BharatBiotechin September said it entered into a licensing agreement with Washington University School of Medicine in St. Louis for a novel "chimp-adenovirus" (Chimpanzee adenovirus), single dose intranasal vaccine for COVID-19.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU